David C. Sachs - 31 Jan 2024 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Chief Financial Officer
Signature
/s/ Jason Liljestrom, as Attorney-in-Fact
Issuer symbol
IBRX
Transactions as of
31 Jan 2024
Net transactions value
-$90,166
Form type
4
Filing time
02 Feb 2024, 19:33:57 UTC
Previous filing
03 Jan 2024
Next filing
26 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $0 +70,745 +50% $0.000000 212,673 31 Jan 2024 Direct
transaction IBRX Common Stock Tax liability $90,166 -26,835 -13% $3.36 185,838 31 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -70,745 -100% $0.000000* 0 31 Jan 2024 Common Stock 70,745 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2 Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the shares subject to the RSU award vested on September 1, 2023 and 70,745 of the shares vested on January 31, 2024.